FDA grants priority review for Pfizer's Talzenna and Xtandi combo in prostate cancer
Tweet Send to a Friend
Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration has accepted for priority review a supplemental New ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
